SermorelinStudienlage & Dosis

Top-Studien zu Sermorelin

Sortiert nach einflussreichen Zitationen und Erscheinungsjahr.

1. 01

   Gonadotrophin-releasing hormone antagonists for assisted reproductive technology.

   The Cochrane database of systematic reviews·2016·n=12.212148 einflussreiche Zitationen

   <h4>Background</h4>Gonadotrophin-releasing hormone (GnRH) antagonists can be used to prevent a luteinizing hormone (LH) surge during controlled ovarian hyperstimulation (COH) without the hypo-oestrogenic side-effects, flare-up, or long…

2. 02

   Long-Acting Growth Hormone Therapy in Pediatric Growth Hormone Deficiency: A Consensus Statement.

   The Journal of clinical endocrinology and metabolism·2025107 einflussreiche Zitationen

   <h4>Context</h4>Several long-acting growth hormone (LAGH) therapies have recently become available, but guidance on their usage in children with growth hormone (GH) deficiency is limited.<h4>Methods</h4>International experts in pediatric…

3. 03

   Ghrelin: An Emerging Therapy for Heart Failure

   Clinical Endocrinology·202555 einflussreiche Zitationen

   <h4>Objective</h4>Ghrelin is emerging as a promising therapeutic option for heart failure (HF) due to its potent inotropic, anabolic, and cardioprotective properties. This review aims to critically examine the available clinical evidence…

4. 04

   Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in-vitro fertilization: a systematic review and meta-analysis.

   Human reproduction update·2009·n=16942 einflussreiche Zitationen

   <h4>Background</h4>Whether the addition of growth hormone (GH) can improve the probability of pregnancy in poor responders undergoing ovarian stimulation for in-vitro fertilization (IVF) has been examined to date by several underpowered…

5. 05

   The effectiveness of GnRHa with and without 'add-back' therapy in treating premenstrual syndrome: a meta analysis.

   BJOG : an international journal of obstetrics and gynaecology·200437 einflussreiche Zitationen

   <h4>Objective</h4>To determine the effectiveness of gonadotrophin-releasing hormone analogues (GnRHa) with and without hormonal add-back therapy in the management of premenstrual syndrome.<h4>Design</h4>Randomised controlled trials were…

6. 06

   Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis.

   European journal of endocrinology·2012·n=3.40032 einflussreiche Zitationen

   <h4>Objective</h4>To summarise the evidence about the efficacy and safety of using GH in adults with GH deficiency focusing on quality of life and body composition.<h4>Data sources</h4>We searched MEDLINE, EMBASE, Cochrane CENTRAL, Web of…

7. 07

   Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis.

   Syst Rev·2016·n=86.881Meta-Analysis32 einflussreiche Zitationen

   <h4>Background</h4>Use of menopausal hormonal therapy (MHT)-containing estrogen and a synthetic progestin is associated with an increased risk of breast cancer. It is unclear if progesterone in combination with estrogen carries a lower…

8. 08

   Online large volume sample staking preconcentration and separation of enantiomeric GHRH analogs by capillary electrophoresis.

   Electrophoresis·2023E30 einflussreiche Zitationen

   A capillary electrophoresis method is proposed to analyze the four most well-known growth hormone-releasing hormone (GHRH) analogs that are misused by athletes. Dimethyl-&#x3b2;-cyclodextrin used as a chiral selector allowed, for the first…

9. 09

   Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation.

   Health technology assessment (Winchester, England)·201029 einflussreiche Zitationen

   <h4>Background</h4>Recombinant human growth hormone (rhGH) is licensed for short stature associated with growth hormone deficiency (GHD), Turner syndrome (TS), Prader-Willi syndrome (PWS), chronic renal insufficiency (CRI), short stature…

10. 10

    Utilizing Somapacitan, a Long-acting Growth Hormone Formulation, for the Treatment of Adult Growth Hormone Deficiency: A Guide for Clinicians.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·202429 einflussreiche Zitationen

    <h4>Objective</h4>Somapacitan is the first approved and currently the only long-acting growth hormone (GH) formulation in the United States for treatment of adults with growth hormone deficiency (GHD). The aim of this review was to provide…

Häufige Fragen